Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients
Status:
Unknown status
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
- To estimate the incidence rates of post-transplant lymphoproliferative disorder (PTLD)
in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept
at the time of transplantation
- To estimate the incidence rates of PTLD in adult, EBV seropositive, kidney alone
transplant recipients treated with calcineurin inhibitors (CNI)-based regimens at the
time of transplantation
- To compare the PTLD incidence rates in adult, EBV seropositive, kidney alone transplant
recipients treated with belatacept to the rates in adult, EBV seropositive, kidney alone
transplant recipients treated with CNI-based regimens at the time of transplantation